Physician profile
David A Sherris
NPI 1689646739
$3,461.82
in general payments reported to CMS, 2019-2025
13 companies · $61.07 in 2025
The $61.07 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,720 · 2020: $195 · 2021: $180 · 2022: $15.90 · 2023: $34.63 · 2024: $255 · 2025: $61.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,894.55 | 2019-2021 | |
| Aerin Medical INC. | $235.22 | 2020-2024 | |
| Medtronic, INC. | $61.07 | 2025 | Straightshot, Stealthstation S8 Platform |
| Optinose US, INC. | $49.15 | 2020-2022 | |
| Karl Storz Endoscopy-America | $42.83 | 2021 | |
| Genzyme Corporation | $36.77 | 2019-2023 | |
| Stryker Corporation | $30.32 | 2021 | |
| Galderma Laboratories, L.P. | $21.72 | 2021 | |
| Aesculap, INC. | $21.37 | 2024 | Elan 4 |
| Abbvie INC. | $20.98 | 2024 | |
| Glaxosmithkline, LLC. | $16.31 | 2023 | Nucala |
| Allergan, INC. | $15.95 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sherris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.